---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-016113"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2023-09-28T23:59:59+00:00"
generated_at: "2026-06-10T07:36:19.768802+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Verastem reports 42% ORR in FRAME study for avutometinib/defactinib in LGSOC

## Summary
- Overall response rate 42% (11/26) in evaluable recurrent LGSOC patients.
- ORR 58% in KRAS mutant LGSOC (7/12) vs 33% in KRAS wild-type (4/12).
- Median duration of response 26.9 months; median PFS 20.0 months.
- 19% of patients (5/26) remained on treatment at data cutoff, minimum 17 months follow-up.
- RAMP 201 Part A confirmed 45% ORR by independent review reported at ASCO 2023.

## SEC filing metadata
- accession: 0001558370-23-016113
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2023-09-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000155837023016113/0001558370-23-016113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000155837023016113/vstm-20230928x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-016113
- JSON: https://secwatch.observer/filing/0001558370-23-016113.json
- Plain text: https://secwatch.observer/filing/0001558370-23-016113.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.